These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22820678)

  • 1. Different intravenous contrast media concentrations do not affect clinical assessment of 18F-fluorodeoxyglucose positron emission tomography/computed tomography scans in an intraindividual comparison.
    Prechtel HW; Verburg FA; Palmowski M; Krohn T; Pietsch H; Kuhl CK; Mottaghy FM; Behrendt FF
    Invest Radiol; 2012 Sep; 47(9):497-502. PubMed ID: 22820678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiphase CT scanning and different intravenous contrast media concentrations in combined F-18-FDG PET/CT: Effect on quantitative and clinical assessment.
    Rebière M; Verburg FA; Palmowski M; Krohn T; Pietsch H; Kuhl CK; Mottaghy FM; Behrendt FF
    Eur J Radiol; 2012 Aug; 81(8):e862-9. PubMed ID: 22591760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging.
    Brechtel K; Klein M; Vogel M; Mueller M; Aschoff P; Beyer T; Eschmann SM; Bares R; Claussen CD; Pfannenberg AC
    J Nucl Med; 2006 Mar; 47(3):470-6. PubMed ID: 16513616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body surface area adapted iopromide 300 mg/ml versus 370 mg/ml contrast medium injection protocol: influence on quantitative and clinical assessment in combined PET/CT.
    Verburg FA; Apitzsch J; Lensing C; Kuhl CK; Pietsch H; Mottaghy FM; Behrendt FF
    Eur J Radiol; 2013 Dec; 82(12):2348-52. PubMed ID: 24113432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of different contrast medium concentrations and injection protocols on quantitative and clinical assessment of FDG-PET/CT in lung cancer.
    Verburg FA; Kuhl CK; Pietsch H; Palmowski M; Mottaghy FM; Behrendt FF
    Eur J Radiol; 2013 Oct; 82(10):e617-22. PubMed ID: 23880426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing positron emission tomography image acquisition protocols in integrated positron emission tomography/magnetic resonance imaging.
    Hartung-Knemeyer V; Beiderwellen KJ; Buchbender C; Kuehl H; Lauenstein TC; Bockisch A; Poeppel TD
    Invest Radiol; 2013 May; 48(5):290-4. PubMed ID: 23399811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
    Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
    Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardized uptake values of uterine leiomyoma with 18F-FDG PET/CT: variation with age, size, degeneration, and contrast enhancement on MRI.
    Kitajima K; Murakami K; Yamasaki E; Kaji Y; Sugimura K
    Ann Nucl Med; 2008 Jul; 22(6):505-12. PubMed ID: 18670857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer.
    Strobel K; Heinrich S; Bhure U; Soyka J; Veit-Haibach P; Pestalozzi BC; Clavien PA; Hany TF
    J Nucl Med; 2008 Sep; 49(9):1408-13. PubMed ID: 18703604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT compared to standard contrast-enhanced CT for characterization and staging of pulmonary tumors eligible for surgical resection.
    Quaia E; Tona G; Gelain F; Lubin E; Pizzolato R; Boscolo E; Bussoli L
    Acta Radiol; 2008 Nov; 49(9):995-1004. PubMed ID: 18651256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of delayed enhanced CT and 18F-FDG PET/CT in the evaluation of adrenal masses in oncology patients.
    Park BK; Kim CK; Kim B; Choi JY
    J Comput Assist Tomogr; 2007; 31(4):550-6. PubMed ID: 17882030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastasis: comparison with ultrasonography and contrast-enhanced CT.
    Monzawa S; Adachi S; Suzuki K; Hirokaga K; Takao S; Sakuma T; Hanioka K
    Ann Nucl Med; 2009 Dec; 23(10):855-61. PubMed ID: 19876704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Truncation artifact on PET/CT: impact on measurements of activity concentration and assessment of a correction algorithm.
    Mawlawi O; Erasmus JJ; Pan T; Cody DD; Campbell R; Lonn AH; Kohlmyer S; Macapinlac HA; Podoloff DA
    AJR Am J Roentgenol; 2006 May; 186(5):1458-67. PubMed ID: 16632745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study.
    Iagaru A; Mittra E; Yaghoubi SS; Dick DW; Quon A; Goris ML; Gambhir SS
    J Nucl Med; 2009 Apr; 50(4):501-5. PubMed ID: 19289439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
    Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
    Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography/computed tomography for staging and restaging of head and neck cancer: comparison with positron emission tomography read together with contrast-enhanced computed tomography.
    Goerres GW; Schuknecht B; Schmid DT; Stoeckli SJ; Hany TF
    Clin Imaging; 2008; 32(6):431-7. PubMed ID: 19006770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor volume assessment by 18F-FDG PET/CT in patients with oral cavity cancer with dental artifacts on CT or MR images.
    Baek CH; Chung MK; Son YI; Choi JY; Kim HJ; Yim YJ; Ko YH; Choi J; Cho JK; Jeong HS
    J Nucl Med; 2008 Sep; 49(9):1422-8. PubMed ID: 18703597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma.
    Graafland NM; Leijte JA; Valdés Olmos RA; Hoefnagel CA; Teertstra HJ; Horenblas S
    Eur Urol; 2009 Aug; 56(2):339-45. PubMed ID: 19477581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.